Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer’s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial

Abstract Background Our previous studies showed that GV1001 has various protective effects against β-amyloid and other stressors. Based on these findings, we hypothesized that GV1001 might have beneficial effects in patients with Alzheimer’s disease (AD). Methods A phase 2, double-blind, parallel-gr...

Full description

Bibliographic Details
Main Authors: Seong-Ho Koh, Hyuk Sung Kwon, Seong Hye Choi, Jee Hyang Jeong, Hae Ri Na, Chan Nyoung Lee, YoungSoon Yang, Ae Young Lee, Jae-Hong Lee, Kyung Won Park, Hyun Jeong Han, Byeong C. Kim, Jin Se Park, Jee-Young Lee, Sangjae Kim, Kyu-Yong Lee
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
GV1001
Efficacy
Safety
Alzheimer’s disease
Clinical trial
Online Access:https://doi.org/10.1186/s13195-021-00803-w

Internet

https://doi.org/10.1186/s13195-021-00803-w

Similar Items